Lincotek and Promimic Expand Partnership for HAnano Surface Technology

Lincotek Group and Promimic have announced a strategic licensing agreement to integrate Promimic’s HAnano Surface technology into Lincotek’s portfolio. This collaboration will strengthen Lincotek’s position in the medical device industry and broaden Promimic’s global reach in surface treatment technology.

Strengthening the Strategic Partnership

This agreement builds on the existing joint venture, Nano Processing Inc. (NPI), which processes implants with HAnano Surface technology in the US. Now, Lincotek can offer this advanced technology directly to its customers, reinforcing its leadership in the medical device sector.

HAnano Surface: Revolutionizing Implant Technology

HAnano Surface is a bioactive, super-hydrophilic surface treatment for orthopaedic implants. It enhances osseointegration, improving how implants bond to bone. By using nanometre-thin hydroxyapatite (HA) crystals, it boosts biocompatibility, accelerates healing, and ensures long-term success. The collaboration allows Lincotek and Promimic to modify complex implant geometries, including micro-porous structures, without clogging the pores. This feature enhances bone growth and stability, providing superior implant performance.

Magnus Larsson, CEO of Promimic, emphasized the potential of this collaboration. By combining Lincotek’s 3D printing expertise with Promimic’s advanced surface treatment, they can offer more efficient, effective implant solutions. The inclusion of HAnano Surface’s super-hydrophilic properties enhances bone in-growth and promotes better implant integration.

Expanding Global Reach for Implant Solutions

For Promimic, this partnership opens new opportunities in the global orthopaedic market. It allows them to offer their technology to a broader range of customers. Lincotek CEO Andrea Colombo highlighted that this collaboration gives customers easier access to HAnano Surface technology, ensuring better-performing, longer-lasting implants.

Initially focused on the US market, the partnership has global potential. As new opportunities arise, the collaboration positions both companies for growth in the worldwide medical implant sector. This partnership demonstrates their commitment to innovation and improving patient outcomes through advanced implant surface technologies.